Rochester, Minn. — A major U.S.-led cooperative group clinical trial coordinated by Mayo Clinic researchers has found that extending maintenance therapy with lenalidomide beyond two years does not improve overall survival for patients with standard-risk multiple myeloma. The results address a long-standing question in cancer care: when does “continuous” treatment stop paying off? The study … Continue reading Mayo Clinic study finds no survival benefit from longer multiple myeloma maintenance therapy